BeNeLuxBelgiumNetherlandsLuxembourg

Fluorescent tumours in the clinic

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted dyes in patients. Now for the first time, a Dutch-German team of researchers has found a way to convince regulatory authorities that their fluorochromes are safe and can be tested on human subjects. In November, the team got the go-ahead for a Phase I study in breast cancer patients with the fluorochrome IR dye 800 CW (LI-COR Bioscience) coupled to the antibody drug Avastin (Roche).
“Our advantage is that we already have a lot of clinical data about the safety and biodistribution of the cancer therapeutic Avastin, which binds to VEGF produced by cancer cells,” said Werner Scheuer from Pharma Research & Early Development at Roche (Penzberg), who developed the anti­body-flurochrome conjugates in cooperation with Vasilis Ntziachristos (TU Munich) and Go van Dam (Medical College Groningen). In the November issue of the Journal of Nuclear Medicine (52(11): 1778-1785), the authors provided evidence that their cancer imaging agent behaves in animals as Avastin does in humans. For proving safety in humans, they will use microdoses of the dye – 100 times lower than the lowest dose in which the cancer drug shows an effect. “We want to statistically prove that breast cancer patients benefit from image-guided surgery with targeted fluorochromes,” explains Ntziachristos. He has developed a camera system that can identify the tumour margins with seven times better resolution than a surgeon can with the naked eye. A pipeline of antibody-fluorochrome conjugates is already being tested in animals.

BeNeLuxBelgiumNetherlandsLuxembourg

16.05.2007

Wageningen – A Dutch analysis has concluded that the country’s forseen GMO regulations for coexistance are efficient. A preliminary analysis of the two-year program carried out by the University of Wageningen and the Institute...

BeNeLuxBelgiumNetherlandsLuxembourg

16.05.2007

Leiden – Octoplus, a Belgian specialist for the development of improved pharmaceutical products, has acquired the Poly Active drug delivery technology from the US-bio­tech company Isotis Orthobiologics Inc. Octoplus paid a1.3...

BeNeLuxBelgiumNetherlandsLuxembourg

16.03.2007

Ghent – The Belgian product developer Devgen NV has raised a31 million through a placement of shares. The company sold 1.5 million shares at a price of a20.75. The company said that the offering was three times oversubscribed.

BeNeLuxBelgiumNetherlandsLuxembourg

16.03.2007

Leiden – The Netherlands Genomics Ini­tiative (NGI) has decided to review the quality of all its genomic centers, both in terms of scientific achievements and valorisation results. The outcome of the evaluation carried out by...

BeNeLuxBelgiumNetherlandsLuxembourg

16.03.2007

Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has...

Switzerland, BeNeLuxBelgiumNetherlandsLuxembourg

25.01.2007

Brussels/Geneva – After the European Commission approved the planned acquisition of Serono SA by Merck KGaA without any restrictions by mid-December, Merck in January made a public tender offer under Swiss law to the shareholders...

Germany, BeNeLuxBelgiumNetherlandsLuxembourg

24.01.2007

Leuven – The German Degussa spin-off Elbion AG has acquired the Belgian 4AZA Bioscience NV. The new company will have two clinical compounds including Elbion’s AWD-12-281, a small molecule phosphodiesterase-4 inhibitor in phase...

Germany, BeNeLuxBelgiumNetherlandsLuxembourg

19.01.2007

Rotterdam/Bielefeld – Microbial genome researchers from University Bielefeld have formed a research collaboration with the Dutch-British cosmetics giant Unilever in the field of deodorants. The partners will identify new...

BeNeLuxBelgiumNetherlandsLuxembourg

21.11.2006

Brussels – Just before the commencement of clinical trials, Ablynx, a Belgian biotech company which is developing a new class of drugs based on DNA, has closed a deal worth up a165 million with the US vaccines specialist Wyeth....

Switzerland, BeNeLuxBelgiumNetherlandsLuxembourg

21.11.2006

London – The Dutch vaccine developer Crucell NV will be concentrating its research and development activities at its headquarters in Leiden. The restructuring will result in the laying-off of 60 Berna staff in Bern. At the end of...

Displaying results 201 to 210 out of 304

< Previous 201-210 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/20/article/fluorescent-tumours-in-the-clinic.html

Image Gallery

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • WILEX (D)0.92 EUR61.4%
  • CO.DON (D)3.30 EUR61.0%
  • BIOTECH PHARMACON (N)17.50 NOK59.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.9%
  • BIONOR PHARMA (N)2.11 NOK-47.6%
  • GW PHARMACEUTICALS (UK)219.25 GBP-40.4%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 18.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper